Development of a Pediatric Tuberculosis Diagnostic Test

Background

The inadequate sensitivity of available organism-based TB diagnostic tools in children, the wide spectrum of disease observed in children, and the non-specific signs and symptoms especially in young and HIV-children, contribute to diagnostic delay and missed opportunities to detect childhood TB.

Technology

Researchers at Stony Brook have identified changes in a serum lipoprotein that result from a combination of host and TB pathogen activity. The MTB-modified lipoprotein (TLP) is thereby a more specific diagnostic marker for TB disease than the conventional host markers. Development of antibodies against the TLP marker enables the production of a simple in-vitro diagnostic (IVD) assay for pediatric tuberculosis using as finger-prick blood or serum.

Advantages

Non-sputum based diagnostic ELISA test - Novel marker - Novel antibodies to TLP

Application

Diagnostic test for pediatric and adult TB.

Patent Status

Patent application submitted

Stage Of Development

Data using serum from pediatric patients. PCT application filed

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook is seeking a commercial partner for licensing and/or collaborative research.

Additional Info

Additional Information:

https://stonybrook.technologypublisher.com/files/sites/050-8896----development-of-a-pediatric-tuberculosis-diagnostic-test.jpg Source: andriano_cz, stock.adobe.com/uk/175903167, stock.adobe.com